In HCC, the upregulation of CRKL prevents β-catenin degradation via the proteasome, promoting the expression of VEGF-A and CXCL1 and subsequently facilitating the recruitment and activation of PD-L1+ TANs[52]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.